patent

Strengthens its Broad and Deep microRNA Intellectual Property for microRNA-based Diagnostics

PHILADELPHIA and REHOVOT, Israel, May 9, 2011 /PRNewswire/ — Rosetta Genomics (NASDAQ: ROSG) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,943,745, which is related to human hsa-miR-497 and its variants and covers the composition of matter.

Human hsa-miR-497 is an important component of the Company’s miRview™ mets and mets2 diagnostic tests for the accurate identification of the tissue of origin in Cancers of Unknown Primary (CUP) and difficult to diagnose metastatic cancer cases. Rosetta Genomics recently announced the launch of an oncology sales team for these advanced microRNA-based diagnostic tests in the United States.

“We remain focused on building an exceptionally strong intellectual property portfolio that allows us to support and protect our products and processes. This is particularly important as we recently launched our first company-led commercialization efforts in the U.S., and this patent provides a further barrier to entry for would-be competitors,” commented Kenneth A. Berlin, President and Chief Executive Officer. “As pioneers in the microRNA field, we believe that Rosetta has the broadest and [click to continue…]

Incoming search terms for this article:

{ 0 comments }

Business Wire 1/25/09

The newly allowed claims cover miR-21, a microRNA that has been linked to a variety of diseases, including cancer, fibrosis, and heart disease. The claims additionally encompass single-stranded and double-stranded antisense compounds complementary to miR-21. The allowance of this second Tuschl III patent in the U.S. extends the scope of this patent estate, which has already yielded patents directed to miR-122 in the U.S. (U.S. Patent No. 7,232,806), Australia (Australia Patent No. 2002 347 035), and Japan (Japan Patent No. 4 371 812). (read more…)

Incoming search terms for this article:

{ 0 comments }